Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis.

Daniel A HochfellnerRaphael RainerHaris ZikoFelix AbererAmra SimicKatharina M LichteneggerPeter BeckKlaus DonsaThomas R PieberFriedrich M FruhwaldAlexander R RosenkranzLars-Peter KamolzPetra M BaumannJulia Katharina MaderJohannes Plank

Published in: Diabetes, obesity & metabolism (2021)

When using well-titrated basal-bolus insulin therapy in hospitalized patients with type 2 diabetes, the basal insulin dose does not require adjustment during fasting periods to achieve safe glycaemic control, provided meal-related bolus insulin is omitted and correction bolus insulin is tailored to glucose levels.

Keyphrases

type diabetes
glycemic control
blood glucose
insulin resistance
stem cells
metabolic syndrome
smoking cessation
weight loss